Recipharm unveils serialisation pricing model
New pricing structure will see the removal of any upfront investment costs for pharmaceutical companies looking to access the CDMO’s serialisation capabilities.
Contract development and manufacturing organisation (CDMO) Recipharm has unveiled plans to improve the affordability of serialisation, with the introduction of a novel pricing model aimed at keeping investment costs down for clients.
The company has devised a pricing structure that will see the removal of any upfront investment costs for pharmaceutical companies looking to access the CDMO’s serialisation capabilities.
Recipharm will offer a standard solution across 14 locations in Europe and more than 70 production lines, with a fixed service fee per pack for all customers. Each serialised product will be compliant with the pending US and EU regulations, with any customisation of the pack offered separately.
The announcement comes as the pharmaceutical industry faces the daunting task of meeting new legal requirements for the serialisation of licensed drug products from November 2017 in the US and early 2019 in Europe.
Companies must adapt their packs, implement their tamper evidence capability and establish the systems, processes and data to comply with the EU Falsified Medicines Directive ‘Safety Features’ Commission Delegated Regulation 2016/161 and the US Drug Supply Chain Security Act (DSCSA), something that is expected to require significant financial investment.
As part of its commitment to actively help pharmaceutical companies prepare for the regulatory changes, Recipharm recently announced plans to invest €40m over the next 3 years to ensure state-of-the-art solutions for serialisation processes. As soon as the service is operational, the company will provide serialisation free-of-charge until the legal requirements come into effect to ensure drug developers are prepared ahead of the deadlines.
The CDMO’s company-wide serialisation project is being led by Staffan Widengren, Director Corporate Projects at Recipharm. He said: “We have spoken to our clients and conducted extensive research to help us fully understand the main challenges associated with the looming requirement for serialisation. Many companies are behind in their preparations, not fully aware of the scale and complexity of the task ahead and concerned about the required financial investment.
“As a result of this consultation exercise, we have created a pricing model designed to spread the cost of serialisation across each customer’s on-going supply agreement as opposed to them needing to make a major upfront investment. From 2023, we will extend this further, ensuring that serialisation is included as standard as part of our product manufacturing costs.
“Having provided serialised products in Asia for a number of years, we understand the scale of the investment involved so are utilising our experience, technologies and capabilities to reduce costs for companies in Europe and the US.”
The industry-wide serialisation, aggregation and verification directive is expected to improve traceability of drugs, help in the fight against counterfeit products entering the supply chain and ultimately improve patient safety.
Recipharm serves 250+ customers and expects 85% of its production to require serialisation.
Kjell Johansson, President Manufacturing Services Europe, added: “Those companies who fail to prepare for the new regulations will face major disruption to their product supply. Recipharm aims to simplify the process by offering a standard solution with a fixed price per unit with the option to customise packs to individual requirements. There will also be no volume commitment needed from customers wishing to access our serialisation services.
“We have also considered the financial implications of aggregation and can include this service from 2017 on customer request. The ability to minimise upfront investment will enable compliance with the new regulations, while reducing financial burden.”
Recipharm is preparing a range of educational papers aimed at training staff internally across its global network and supporting customers with the challenges of serialisation, verification and complying with new regulatory requirements.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance